Additionally, the anti-tumor activity of CB839 in xenograft growth of PIK3CA-mutant CRC cells was enhanced by chemotherapeutic agent 5-fluorouracil without obvious dose-limiting toxicity, indicating the potential of the combination therapy for patients with PIK3CA-mutant colorectal cancer [268]. Here, PIK3CA is linked to colorectal cancer.